GE HealthCare Technologies, a NASDAQ-listed digital healthcare company, has begun pre-marketing for the carve-out sale of its China imaging business, said three sources familiar with the situation.

Major private equity firms have been approached by the sellside, they said. The official process is expected to kick off in the second half of this year, said the first source. Deal size is expected at single-digit billions of USD, said the second source.

GE’s imaging business includes CT, PET CT, MRI and other imaging equipment, which faces severe competition in China, especially from the listed local rival Shanghai United Imaging, said the third source.

The procurement of the large medical equipment market dominated by China’s public hospitals would face challenges in procuring US brands amid geopolitical tensions, said the first source.

The source noted that Chinese background owner could make the brand easier to participate in the tender procurement.

Though with strong competition from Shanghai United Imaging, GE HealthCare still has its own value and brand recognition in high-end large equipment, he said.

GE HealthCare Technologies has a current market capitalization of USD 39.8bn, with a 19x price-to-earnings ratio.

Goldman Sachs and Morgan Stanley are working to arrange the China business sale, according to a report by this news service in November 2025.

A spokesperson for GE HealthCare said, “We don’t comment on market rumors. China is one of the world’s largest healthcare markets, and we remain committed to serving patients and customers there.”

Goldman Sachs and Morgan Stanley did not immediately respond to requests for comments.